Axol Biosciences’ CiPA validated ventricular cardiomyocytes can be used as a robust cardiotoxicity measurement tool.
Axol Biosciences, a provider of induced pluripotent stem cell (ISPC)-derived cells, media and characterization services for life science discovery, announced that its IPSC-derived ventricular cardiomyocytes have undergone comprehensive analysis in vitro validation of the pro-arrhythmia assay (CiPA) on June 7, 2022. This assay showed that the cells were suitable for measuring cardiotoxicity, providing scientists with a robust cardiac model for drug discovery and screening.
CiPa is a task force developed by the FDA to evaluate the utility of iPSC-derived human ventricular cardiomyocytes in reproducing cardiotoxicity in a dish. The test tests cells with 28 compounds known to be cardiotoxic and induce the fatal arrhythmia “Torsades de Pointes”. According to an Axol press release, Clyde BioSciences, a contract research organization specializing in cardiotoxicity testing, used this test to validate Axol’s cardiomyocytes for cardiac safety testing.
“As a core member of the CiPA initiative, we are delighted to have supported Axol’s cell development and helped the team assess the performance of their cardiomyocytes,” said Godfrey Smith, Chief Scientific Officer of Clyde Biosciences, in the press release. “After running the CiPA protocol on Clyde’s proprietary CellOPTIQ platform and providing data analysis and interpretation, we confirm that our data indicate that Axol cardiomyocytes meet the prediction requirements. in vitro pro-arrhythmia screening.
Axol’s human iPSC-derived ventricular cardiomyocytes provide a continuous source of cells of the same genetic background for use in multiple experiments and physiologically relevant analysis in vitro human heart cell research model. This enables reliable and reproducible cardiotoxicity testing for drug candidates on a large scale.
“Scientists need cells and reagents they can rely on to perform meaningful toxicity assessments of drug candidates, before advancing candidates to the clinic,” said Liam Taylor, CEO of Axol Bioscience, in the press release. “We are both delighted and proud to demonstrate the suitability of our iPSC-derived human ventricular cardiomyocytes for toxicity testing. Axol’s strict quality control standards mean we have the ability to produce reliable, validated cells that scientists can use to assess a compound’s cardiac liability and ultimately help improve the discovery process. of drugs.
Source: Axol Biosciences
